US lobbies for co-pay scrapping for poorer seniors

24 March 2008

A US congressional initiative, which is endorsed by the Assisted Living Federation of America, to eliminate the prescription drug expense paid by poor seniors who live in assisted-living communities has been filed on Capitol Hill. Representatives Lloyd Doggett (Democrat, Texas) and Lincoln Diaz-Balart (Republican, Florida) and 12 other House members are sponsoring HR 5604, the Medicare Part D Home and Community Services Co-payment Equity Act of 2008.

The ALFA argues that the bipartisan measure "corrects an apparent oversight in the Medicare Part D prescription drug program [Marketletters passim] by exempting drug co-payments for residents in assisted-living and other home and community-based settings who qualify for both Medicare and Medicaid." The new legislation would treat these dual-eligible recipients the same as Medicaid recipients in nursing homes.

"It is simply wrong that any Medicaid recipient pay a financial penalty for living in an assisted living community," said Richard Grimes, the ALFA's president. He added: "we are grateful members of Congress from both political parties recognize this inequity and are taking steps to correct it." The ALFA represents professionally-managed, assisted-living communities for seniors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight